Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Residual pulmonary hypertension after pulmonary endarterectomy: A meta-analysis

WC. Hsieh, P. Jansa, WC. Huang, M. Nižnanský, M. Omara, J. Lindner,

. 2018 ; 156 (3) : 1275-1287. [pub] 20180517

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, metaanalýza

Perzistentní odkaz   https://www.medvik.cz/link/bmc19035188

OBJECTIVE: Chronic thromboembolic pulmonary hypertension is surgically treated through pulmonary endarterectomy. Although pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension in terms of both functional outcomes and survival, many patients experience persistent pulmonary hypertension after pulmonary endarterectomy. The study objective was to calculate the pooled estimates of outcomes after pulmonary endarterectomy, including persistent pulmonary hypertension. METHODS: Meta-analyses were conducted on published studies reporting residual/persistent/recurrent pulmonary hypertension in 4868 patients with chronic thromboembolic pulmonary hypertension after pulmonary endarterectomy. The rate of persistent pulmonary hypertension and change in mean pulmonary artery pressure, pulmonary vascular resistance, and 6-minute walk distance after pulmonary endarterectomy were outcomes of interest. RESULTS: Twenty-five percent of patients with chronic thromboembolic pulmonary hypertension were diagnosed with persistent pulmonary hypertension after pulmonary endarterectomy. Pulmonary endarterectomy reduced mean pulmonary artery pressure and pulmonary vascular resistance by approximately 21 mm Hg (standardized mean difference, 1.75; 95% confidence interval, -1.62 to 1.88; P < .00001) and 561 dyn.s/cm5 (standardized mean difference, 1.64; 95% confidence interval, -1.58 to 1.70; P < .00001), respectively. Conversely, 6-minute walk distance increased by 96 m (standardized mean difference, -0.83; 95% confidence interval, -0.91 to -0.76; P < .00001) after pulmonary endarterectomy. CONCLUSIONS: Pulmonary endarterectomy is the gold standard treatment for chronic thromboembolic pulmonary hypertension and provides immediate correction of hemodynamic parameters in most patients. However, in up to one quarter of operable cases, pulmonary hypertension persists after surgery. In those patients with persistent pulmonary hypertension, continued medical management with newer agents may be required to improve pulmonary hemodynamics and, therefore, patient outcomes.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19035188
003      
CZ-PrNML
005      
20191014122323.0
007      
ta
008      
191007s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jtcvs.2018.04.110 $2 doi
035    __
$a (PubMed)29903403
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hsieh, Wan Chin $u First Faculty of Medicine, Charles University, Prague, Czech Republic; 2nd Department of Cardiovascular Surgery, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
245    10
$a Residual pulmonary hypertension after pulmonary endarterectomy: A meta-analysis / $c WC. Hsieh, P. Jansa, WC. Huang, M. Nižnanský, M. Omara, J. Lindner,
520    9_
$a OBJECTIVE: Chronic thromboembolic pulmonary hypertension is surgically treated through pulmonary endarterectomy. Although pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension in terms of both functional outcomes and survival, many patients experience persistent pulmonary hypertension after pulmonary endarterectomy. The study objective was to calculate the pooled estimates of outcomes after pulmonary endarterectomy, including persistent pulmonary hypertension. METHODS: Meta-analyses were conducted on published studies reporting residual/persistent/recurrent pulmonary hypertension in 4868 patients with chronic thromboembolic pulmonary hypertension after pulmonary endarterectomy. The rate of persistent pulmonary hypertension and change in mean pulmonary artery pressure, pulmonary vascular resistance, and 6-minute walk distance after pulmonary endarterectomy were outcomes of interest. RESULTS: Twenty-five percent of patients with chronic thromboembolic pulmonary hypertension were diagnosed with persistent pulmonary hypertension after pulmonary endarterectomy. Pulmonary endarterectomy reduced mean pulmonary artery pressure and pulmonary vascular resistance by approximately 21 mm Hg (standardized mean difference, 1.75; 95% confidence interval, -1.62 to 1.88; P < .00001) and 561 dyn.s/cm5 (standardized mean difference, 1.64; 95% confidence interval, -1.58 to 1.70; P < .00001), respectively. Conversely, 6-minute walk distance increased by 96 m (standardized mean difference, -0.83; 95% confidence interval, -0.91 to -0.76; P < .00001) after pulmonary endarterectomy. CONCLUSIONS: Pulmonary endarterectomy is the gold standard treatment for chronic thromboembolic pulmonary hypertension and provides immediate correction of hemodynamic parameters in most patients. However, in up to one quarter of operable cases, pulmonary hypertension persists after surgery. In those patients with persistent pulmonary hypertension, continued medical management with newer agents may be required to improve pulmonary hemodynamics and, therefore, patient outcomes.
650    _2
$a dospělí $7 D000328
650    _2
$a endarterektomie $x škodlivé účinky $7 D004691
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a plicní hypertenze $x epidemiologie $x etiologie $7 D006976
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a plicní embolie $x chirurgie $7 D011655
650    _2
$a plicní tlak v zaklínění $7 D011669
650    _2
$a rizikové faktory $7 D012307
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a metaanalýza $7 D017418
700    1_
$a Jansa, Pavel $u Pulmonary Hypertension Center, 2nd Internal Clinic, General University Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Huang, Wei Chun $u Critical Care and Cardiovascular Medical Center, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan; College of Medicine, National Yang-Ming University, Taipei, Taiwan; Department of Physical Therapy, Fooyin University, Kaohsiung, Taiwan.
700    1_
$a Nižnanský, Matus $u 2nd Department of Cardiovascular Surgery, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
700    1_
$a Omara, Mohamend $u Department of Thoracic and Cardiovascular Surgery, Research Institute, Cleveland Clinic, Cleveland, Ohio.
700    1_
$a Lindner, Jaroslav $u 2nd Department of Cardiovascular Surgery, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. Electronic address: jaroslav.lindner@lf1.cuni.cz.
773    0_
$w MED00003020 $t The Journal of thoracic and cardiovascular surgery $x 1097-685X $g Roč. 156, č. 3 (2018), s. 1275-1287
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29903403 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191014122747 $b ABA008
999    __
$a ok $b bmc $g 1451848 $s 1073738
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 156 $c 3 $d 1275-1287 $e 20180517 $i 1097-685X $m Journal of thoracic and cardiovascular surgery $n J Thorac Cardiovasc Surg $x MED00003020
LZP    __
$a Pubmed-20191007

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...